Healthcare · Biotechnology
Price
$7.00
Market Cap
$29.5M
Employees
18
Beta
0.16
Avg Volume
28,685
CEO
Ryan H. Saadi
Business Description
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Business History
Price Overview
Last updated: Jun 27, 2026 10:07am (just now)$7.00
-2.72 (-27.98%)
Day Range
$7.00 – $9.82
52-Week Range
$4.14 – $71.00
50-Day MA
$8.57
200-Day MA
$17.55
Volume
76,463.00
Share Structure
Outstanding
4,219,343.00
Float
1,074,053.00
Free Float
25.5%
Low free float
— 25.5% of shares trade freely, ~74.5% held by insiders/institutions
Below average liquidity. Large orders can move the price significantly. Insiders or strategic holders control the majority — watch for lockup expirations or secondary offerings.
Small absolute float (1.1M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.87
Stock Price: $7.00
EPS (Diluted): -8.08
EPS (Diluted): -8.08
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-6.68
Stock Price: $7.00
Total Equity: -$8.23M
Shares: 3,319,812
Total Equity: -$8.23M
Shares: 3,319,812
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.53
Market Cap: $29.54M
Total Debt: $3.10M
Cash: $552,372
EBITDA: -$25.57M
Total Debt: $3.10M
Cash: $552,372
EBITDA: -$25.57M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$57.5M
Market Cap: $29.54M
Total Debt: $3.10M
Cash: $552,372
Total Debt: $3.10M
Cash: $552,372
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $7.00
Revenue: $0.00
Shares: 3,319,812
Revenue: $0.00
Shares: 3,319,812
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$26.14M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$26.28M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
241.4%
Net Income: -$26.28M
Total Equity: -$8.23M
Total Equity: -$8.23M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
5,744.3%
Operating Income: -$26.14M
Tax Rate: 0.0%
Equity: -$8.23M
Total Debt: $3.10M
Cash: $552,372
Tax Rate: 0.0%
Equity: -$8.23M
Total Debt: $3.10M
Cash: $552,372
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.22
Current Assets: $1.54M
Current Liabilities: $7.07M
Current Liabilities: $7.07M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.38
Short-Term Debt: $1.98M
Long-Term Debt: $1.12M
Total Debt: $3.10M
Total Equity: -$8.23M
Long-Term Debt: $1.12M
Total Debt: $3.10M
Total Equity: -$8.23M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 3,319,812
Shares: 3,319,812
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-2.48
Total Equity: -$8.23M
Shares: 3,319,812
Shares: 3,319,812
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-3.73
Operating CF: -$12.33M
CapEx: -$64,439
Shares: 3,319,812
CapEx: -$64,439
Shares: 3,319,812
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $7.00
Stock Price: $7.00
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$26.28M
Net Income: -$26.28M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares TVGN against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 1:37pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $378,357 | $403,581 | $0 |
| Gross Profit | $0 | $0 | $-378,357 | $-403,581 | $0 |
| Operating Expenses | $4.6M | $953,083 | $8.5M | $53.2M | $26.1M |
| Operating Income | -$4.6M | $-953,083 | -$8.8M | -$53.6M | -$26.1M |
| Net Income | -$15.6M | $4.4M | -$60.5M | -$10.1M | -$26.3M |
| EBITDA | -$15.0M | $4.6M | -$58.9M | -$13.1M | -$25.6M |
| EPS | $-16.50 | $1.84 | $-0.02 | $-4.68 | $-8.08 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 1:37pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $7.1M | $5.5M | $1.1M | $1.3M | $552,372 |
| Total Current Assets | $7.2M | $5.8M | $1.7M | $2.4M | $1.5M |
| Total Assets | $7.7M | $7.7M | $5.5M | $3.5M | $4.4M |
| Current Liabilities | $667,944 | $2.0M | $85.5M | $9.0M | $7.1M |
| Long-Term Debt | $23.5M | $39.3M | $14.2M | $1.0M | $1.1M |
| Total Liabilities | $24.1M | $41.7M | $99.9M | $10.1M | $12.6M |
| Total Equity | -$16.5M | -$34.0M | -$94.4M | -$6.7M | -$8.2M |
| Retained Earnings | -$17.1M | -$39.2M | -$99.7M | -$113.4M | -$139.7M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 1:37pm (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$5.3M | -$8.7M | -$8.2M | -$12.0M | -$12.3M |
| Capital Expenditure | $-109,727 | $-479,042 | $-133,000 | $0 | $-64,439 |
| Free Cash Flow | -$5.4M | -$9.1M | -$8.3M | -$12.0M | -$12.4M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$343.0M | $0 | $0 |
| Net Change in Cash | $7.1M | -$1.6M | -$4.4M | $230,598 | $-730,623 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 10:07am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$502.3M $502.3M – $502.3M
|
$1.4B $1.4B – $1.4B
|
$307.4M $307.4M – $307.4M
|
$724.5M $724.5M – $724.5M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$43.2M -$43.2M – -$43.2M
|
-$59.7M -$59.7M – -$59.7M
|
$51.5M $51.5M – $51.5M
|
$182.6M $182.6M – $182.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 1:37pm (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | -6.7% | +100.0% |
| Operating Income Growth | +79.4% | -827.8% | -505.7% | +51.2% |
| Net Income Growth | +128.3% | -1,471.9% | +83.3% | -159.8% |
| EBITDA Growth | +131.0% | -1,369.5% | +77.7% | -94.6% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-10 | Flomenberg Neal | S-Sale | 19.00 | $7.75 | $147 |
| 2026-03-11 | Flomenberg Neal | S-Sale | 452.00 | $7.26 | $3,282 |
| 2026-03-13 | Flomenberg Neal | S-Sale | 501.00 | $6.40 | $3,206 |
| 2025-12-18 | Saadi Ryan H. | G-Gift | 50,000.00 | $0.00 | $0 |
| 2025-12-11 | Desai Kirti | G-Gift | 300,000.00 | $0.00 | $0 |
| 2025-12-11 | Saadi Ryan H. | G-Gift | 460,000.00 | $0.00 | $0 |
| 2025-08-15 | Saadi Ryan H. | G-Gift | 20,000.00 | $0.00 | $0 |
| 2025-06-27 | Saadi Ryan H. | A-Award | 8,000,000.00 | $0.00 | $0 |
| 2025-06-27 | Khan Sadiq | A-Award | 200,000.00 | $0.00 | $0 |
| 2025-06-27 | Flomenberg Neal | A-Award | 300,000.00 | $0.00 | $0 |
| 2025-06-27 | Desai Kirti | A-Award | 750,000.00 | $0.00 | $0 |
| 2025-06-09 | Saadi Ryan H. | S-Sale | 1,438,206.00 | $1.23 | $1.8M |
| 2025-03-12 | Flomenberg Neal | S-Sale | 232,968.00 | $1.09 | $253,935 |
| 2025-03-07 | Flomenberg Neal | S-Sale | 71,273.00 | $1.14 | $81,251 |
| 2025-03-10 | Flomenberg Neal | S-Sale | 70,384.00 | $1.09 | $76,719 |
| 2025-03-11 | Flomenberg Neal | S-Sale | 70,252.00 | $1.05 | $73,765 |
| 2025-03-04 | Flomenberg Neal | S-Sale | 14,639.00 | $1.28 | $18,738 |
| 2025-03-05 | Flomenberg Neal | S-Sale | 110,659.00 | $1.21 | $133,897 |
| 2025-03-06 | Flomenberg Neal | S-Sale | 88,519.00 | $1.10 | $97,371 |
| 2024-12-23 | Feike Jeffrey L. | A-Award | 240,000.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for TVGN — it's generated by the pipeline (
market-narrative step).
No community reviews yet for TVGN.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30